Evidence of in situ estrogen synthesis in nitrosomethylurea-induced rat mammary tumors via the enzyme estrone sulfatase

Journal of Steroid Biochemistry and Molecular Biology

Volumn 58, Issue 4, 1996, Pages 425-429

  Masamura, Shigeru ^a   Santner, Steven J ^a   Santen, Richard J ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLNITROSOUREA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; ESTROGEN SYNTHESIS; FEMALE; ISOTOPE LABELING; LIVER; NONHUMAN; RAT; TECHNIQUE;

ANIMALIA;

EID: 0030200128     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(96)00065-9     Document Type: Article

References (22)

1. 19-steroids and oestradiol levels in human primary breast tumor tissues and their correlation with androgen and oestrogen receptors. J. Steroid Biochem. 24 (1986) 1117-1125.
2. 2. Samojlik E., Santen R. J. and Wells S. A.: Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. J. Clin. Endocr. Metab. 45 (1977) 480-487.
3. 3. Santen R. L., Leszczynski D., Tilson-Mallet N., Feil P. D., Wright C., Manni A. and Santner S. J.: Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase vs sulfatase pathways. In Endocrinology of the Breast: Basic and Clinical Aspects (Edited by A. Angeli, H. L. Bradlow and L. Dogliotte). NY Academy of Science, New York, Vol. 464 (1986) pp. 126-137.
4. 4. Adams J. B. and Li K.: Biosynthesis of 17β-oestradiol in human breast carcinoma tissue and a novel method for its characterization. Br. J. Cancer 31 (1975) 429-433.
5. 19 steroids by human breast cancers. Br. J. Cancer 33 (1976) 116-118.
6. 6. Wilking N., Carlstrom K., Gustafsson S. A., Skoldefors H. and Tollborn O.: Oestrogen receptors and metabolism of oestrone sulfate in human mammary carcinoma. Eur. J. Cancer 16 (1980) 1339-1344.
7. 7. Santner S. J., Feu P. D. and Santen R. J.: In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocr. Metab. 59 (1984) 29-33.
8. 8. Santner S. J., Ohlsson-Wilhelm B. and Santen R. J.: Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures. Int. J. Cancer 54 (1993) 119-124.
9. 9. Santner S. J., Leszczynski D., Wright C., Manni A., Feil P. D. Santen R. J.: Estrone sulfate: a potential source of estradiol in human breast cancer tissues. Breast Cancer Res. Treat. 7 (1986) 35-44.
10. 10. Santner S. J., Levin M. C. and Santen R. J.: Estrone sulfate stimulates growth of nitrosomethylurea-induced carcinoma in vivo in the rat. Int. J. Cancer 46 (1990) 73-78.
11. 11. Reed M. J., Owen A. M., Lai L. C., Coldham N. G., Ghilchik M. W., Shaikh N. A. and James V. H. T.: In situ oestrone synthesis in normal breast and breast tumor tissues: effect of treatment with 4-hydroxyandrostenedione. Int. J. Cancer 44 (1989) 233-237.
12. 12. Stoner E.: The clinical development of a 5α-inhibitor, finasteride. J. Steroid Biochem. Molec. Biol. 37 (1990) 375-378.
13. 13. Silva J. E. and Larsen P. R.: Pituitary nuclear 3,5,3′-triiodothyronine and thyrotropin secretion: an explanation for the effect of thyroxine. Science 198 (1977) 617-620.
14. 14. Vignon F., Terqui M., Westley B., Derocq D. and Rochefort H.: Effects of plasma estrogen sulfates in mammary cancer cells. Endocrinology 106 (1980) 1079-1086.
15. 15. Loza M. C., Valencia A. and Hicks J. J.: Uterine estrogen sulfatase activity. Influence of steroid hormones and adenine nucleotides. J. Steroid Biochem. 36 (1990) 301-303.
16. 16. Pasqualini J. R., Gelly C. and Lecerf R.: Estrogen sulfates: biological and ultrastructural responses and metabolism in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 8 (1986) 233-240.
17. 17. Pasqualini J. R., Schotz B., Varin C. and Nguyen B.-L.: Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer. J. Steroid Biochem. Molec. Biol. 41 (1992) 323-329.
18. 18. Li P.-K., Pillai R., Young B. L., Bender W. H., Marrino D. M. and Liu F.: Synthesis and biochemical studies of estrone sulfatase inhibitors. Steroids 58 (1993) 106-111.
19. 19. Howarth N. M., Purohit A., Reed M. J. and Potter B. V. L.: Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 37 (1994) 219-221.
20. 20. Demers L. M., Lipton A., Harvey H. A., Kambic K. B., Grossberg H., Brady C. and Santen R. J.: The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J. Steroid Biochem. Molec. Biol. 44 (1993) 687-691.
21. 21. Coombes R. C., Goss P. E., Dowsett M., Gazet J. C. and Brodie A. M. H.: 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 2 (1984) 1237-1239.
22. 22. Santner S. J., Chen S., Zhou D., Korsunsky Z., Martel J. and Santen R. J.: Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in culture. J. Steroid Biochem. Molec. Biol. 44 (1993) 611-616.